Investigational drug · Phase 2
TQA3334
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis B.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "TQA3334"
First trial start
2024
Dec 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQA3334", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TQA3334" as an intervention, largest first.
- Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV InfectionPivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06706310 · 116 participants · Start Dec 4, 2024 · Primary completion Dec 7, 2025
Drug: Placebo; TQA3334 Tablet and 1 more · For: Chronic Hepatitis B
Sites: Chongqing, China; Guangzhou, China; Shenzhen, China · 15 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04273815 · 40 participants (planned) · Start Jul 6, 2020 · Primary completion Jan 31, 2021
Drug: TQ-A3334; Anlotinib · For: Non-small Cell Lung Cancer
Sites: Nanjing, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06160895 · 40 participants · Start Dec 26, 2023 · Primary completion Jun 24, 2024
Drug: TQ-A3334 tablets; TQ-A3334 placebo tablets · For: Hepatitis B
Sites: Changchun, China
- A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsTerminated
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06507891 · 30 participants · Start Jul 6, 2020 · Primary completion Aug 25, 2023
Drug: TQ-A3334 tablets; TQ-A3334 tablets + Anlotinib capsules · For: Non Small Cell Lung Cancer
Sites: Nanjing, China
Tongji HospitalAcademic, hospital or other
NCT04202653 · 24 participants · Start Jan 1, 2020 · Primary completion Jun 30, 2023
Drug: ETV; TQ-A3334 and 1 more · For: Chronic Hepatitis b
Sites: Wuhan, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04180150 · 12 participants (planned) · Start Nov 18, 2019 · Primary completion Sep 30, 2020
Drug: TQ-A3334; Placebo and 1 more · For: Chronic Hepatitis B
Sites: Chongqing, China; Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- TLR7 agonist plus anti-PD-L1 enhances HBsAg decline and reinvigorates HBV-specific CD8+ T cells: OCEANcure05 RCT study.
Chen Y, Wu T, Huang D, et al. · Clin Mol Hepatol 2026
- A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
Zuo X, Cheng Q, Wang Z, et al. · Int Immunopharmacol 2024
- Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals.
Hu Y, Zhang H, Wu M, et al. · Expert Opin Investig Drugs 2021
Also in development for Chronic Hepatitis B
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.